This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month
study of the efficacy of abaloparatide in postmenopausal women and men ≥ 50 years of age with
acute fractures of the pelvis (n=78). The primary outcome is CT image based evidence of
fracture healing. The secondary aims are pain and physical performance measures at 3 months.
This study will be extended with 9 months of open label abaloparatide to determine if any
potential differences between the placebo and abaloparatide groups during the 3 months of
treatment are evident and persist over time, even in patients who use abaloparatide after the
three-month placebo controlled intervention.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital for Special Surgery, New York
Collaborators:
Icahn School of Medicine at Mount Sinai Lenox Hill Hospital New York Hospital Queens New York University Weill Medical College of Cornell University